Press release
Neuromodulation Devices Market to Reach USD 10.39 Billion by 2030 Powered by Technological Innovation
Neuromodulation Devices Market
Advancements such as closed-loop sensing technology, rechargeable implantable pulse generators, and MRI-compatible systems are transforming therapeutic outcomes. Spinal cord stimulators hold the largest product share at 39.67%, while Parkinson's disease represents the leading application segment, accounting for 26.90% of the total market in 2024. North America dominates with 43.68% market share, led by strong research funding and rapid adoption of advanced neurotechnologies.
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/neuromodulation-devices-market?utm_source=OpenPR&utm_campaign=Onkar
Key Highlights from the Report
➤ Global neuromodulation devices market to reach USD 10.39 billion by 2030 at 8.51% CAGR.
➤ North America led with a 43.68% market share in 2024, followed by Europe.
➤ Spinal cord stimulators dominated the product segment with 39.67% share.
➤ Parkinson's disease accounted for 26.90% of applications in 2024.
➤ Government funding for neurological disorder research exceeded USD 259 million in the U.S. for Parkinson's alone.
➤ Technological innovations in closed-loop and AI-integrated systems boost patient therapy outcomes.
Market Segmentation
By Product Type:
Spinal cord stimulators remain the dominant category, utilized extensively in managing chronic pain and spinal trauma cases. These systems improve mobility and reduce dependence on opioids, aligning with the shift toward non-pharmaceutical therapies. Deep brain stimulators (DBS) are projected to grow at the highest CAGR of 9.53%, supported by their efficacy in managing Parkinson's, essential tremor, and dystonia. Ongoing approvals and clinical trials for DBS in psychiatric disorders further enhance future potential.
By Application:
Parkinson's disease remains the largest application segment, accounting for over one-fourth of market revenue in 2024. Increasing diagnosis rates and research funding-such as the USD 125 million granted by NINDS in 2023-fuel expansion. Chronic pain treatment is emerging as the fastest-growing segment as neuromodulation devices increasingly replace traditional pain management methods, offering precision stimulation with real-time adjustments.
By End Use:
Hospitals and Ambulatory Surgery Centers (ASCs) collectively lead with the largest market share, as they integrate neuromodulation therapies into standard neurological and pain management programs. The co-adoption of robotic-assisted surgery enhances procedural precision. Clinics and physiotherapy centers are gaining traction due to greater awareness and better accessibility for outpatient neuromodulation treatments.
Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/neuromodulation-devices-market?utm_source=OpenPR&utm_campaign=Onkar
Regional Insights
North America dominates the global neuromodulation devices market, accounting for 43.68% of revenue in 2024, supported by strong technological innovation, high healthcare spending, and favorable reimbursement policies. The U.S. leads within the region due to enhanced awareness, rising chronic pain prevalence, and significant research grants for Parkinson's and Alzheimer's disease.
Europe holds the second-largest share, supported by robust regulatory frameworks, active research funding in neurological healthcare, and the presence of advanced clinical facilities across the UK, Germany, and France. The Asia Pacific region is expected to witness the fastest growth driven by increasing awareness, the establishment of neuromodulation research centers, and a growing patient base in China and Japan. Emerging economies in Latin America and the Middle East & Africa are also showing rising investments in advanced medical devices and chronic pain management solutions.
Market Dynamics
Market Drivers:
Growing prevalence of neurological and chronic pain disorders, combined with advancements in minimally invasive device design, propels market expansion. Increased government and institutional funding for R&D in neurostimulators enhances product innovation and patient access.
Market Restraints:
High device costs, time-intensive regulatory approvals, and variable reimbursement across regions remain challenges. Limited clinical expertise in certain developing markets also restricts widespread adoption.
Market Opportunities:
Integration of artificial intelligence and closed-loop feedback technologies is revolutionizing neuromodulation precision. Expanding applications in mental health disorders, treatment-resistant depression, and stroke rehabilitation represent significant opportunities for next-generation devices.
Purchase This Exclusive Report at Just USD 6051 Only: https://www.datamintelligence.com/buy-now-page?report=neuromodulation-devices-market?utm_source=OpenPR&utm_campaign=Onkar
Reasons to Buy the Report
✔ Detailed segmentation by product type, application, and regional performance.
✔ Comprehensive insights into emerging trends and innovation pipelines.
✔ Evaluation of government and institutional funding supporting neurology R&D.
✔ Comparative analysis of leading market players and their product portfolios.
✔ Reliable CAGR and forecast data validated by DataM Intelligence's research framework.
Frequently Asked Questions (FAQs)
◆ How Big is the Global Neuromodulation Devices Market in 2024?
◆ Who Are the Key Players Driving the Neuromodulation Devices Market Growth?
◆ What is the Projected CAGR of the Neuromodulation Devices Market from 2025 to 2030?
◆ Which Product Segment Dominates the Market in 2024?
◆ Which Region is Expected to Lead Neuromodulation Devices Market Growth by 2030?
Company Insights
Abbott
Medtronic
Boston Scientific Corporation
Nevro Corporation
LivaNova PLC
NeuroPace, Inc.
Nexstim
Axonics, Inc.
electroCore, Inc.
Laborie
Recent Developments:
July 2024: Mainstay Medical received EU and UK approvals for full-body MRI compatibility for its ReActiv8 Restorative Neurostimulation System.
February 2024: Boston Scientific gained FDA approval for expanded indications of the WaveWriter SCS system to address non-surgical low back pain.
January 2024: Abbott launched the Liberta RC DBS system-the world's smallest rechargeable device-for movement disorders.
November 2023: Nevro Corporation acquired Vyrsa Technologies, enhancing its minimally invasive pain therapy portfolio.
Conclusion
The global neuromodulation devices market is poised for sustained growth through 2030 as clinical innovation converges with advanced electronics and biocompatibility. Rising chronic pain prevalence, deeper understanding of neurocircuitry, and AI-integrated closed-loop technologies are reshaping neurological therapy worldwide. Strategic investments, strong regulatory support, and continuous product advancements by leading manufacturers will ensure long-term progress in precision-based neuromodulation and improved patient quality of life.
Contact Us
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com
About Us
DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuromodulation Devices Market to Reach USD 10.39 Billion by 2030 Powered by Technological Innovation here
News-ID: 4235897 • Views: …
More Releases from DataM Intelligence
U.S. Biomaterials Market to Surpass USD 171.3 Billion by 2030 Driven by Advanced …
The U.S. biomaterials market, valued at USD 59.3 billion in 2023, is projected to grow at a strong CAGR of 14.8% from 2024 to 2030, reaching an estimated USD 171.3 billion by 2030, according to DataM Intelligence. This accelerated growth is driven by rising incidences of chronic diseases, increased accidental injuries, and heightened demand for tissue engineering and regenerative medicine applications. Biomaterials-ranging from metallic and polymeric to natural and ceramic…
U.S. Facial Injectable Market to Reach USD 7.64 Billion by 2030 Driven by Aesthe …
U.S. Facial Injectable Market to Reach USD 7.64 Billion by 2030 Driven by Aesthetic Innovation
Market Overview
The U.S. facial injectable market was valued at USD 3.88 billion in 2023 and is projected to grow at a robust CAGR of 11.1% from 2024 to 2030, reaching approximately USD 7.64 billion, according to DataM Intelligence. The market growth is driven by rising awareness of facial aesthetics, the increasing geriatric population, and a growing…
Breast Biopsy Devices Market to Reach USD 3.26 Billion by 2030 Driven by Diagnos …
The global breast biopsy devices market, valued at USD 2,384.1 million in 2025, is projected to reach USD 3,261.7 million by 2030, growing at a CAGR of 6.5%, according to DataM Intelligence. Rising breast cancer prevalence worldwide continues to escalate the demand for early detection and precise diagnostic solutions. The adoption of image-guided biopsy technologies, vacuum-assisted procedures, and minimally invasive methods is transforming diagnostics by improving accuracy while reducing patient…
Europe Sports Nutrition Market to Reach USD 9.20 Billion by 2030 Driven by Perfo …
The Europe sports nutrition market is experiencing strong momentum, standing at USD 6.13 billion in 2025 and projected to attain USD 9.20 billion by 2030, according to DataM Intelligence. This growth, at an impressive 8.47% CAGR, underscores the region's rising integration of sports nutrition into lifestyle and wellness choices. Expanding adoption by millennials, Gen Z, and active seniors is reshaping consumption habits from athletic use to daily health maintenance. The…
More Releases for Neuromodulation
Rising Prevalence Of Neurological Disorders Fuels Growth In The Neuromodulation …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Neuromodulation Market Size By 2025?
In the recent years, the neuromodulation market size has seen robust growth. The market, worth $6.96 billion in 2024, is anticipated to increase to $7.62 billion in 2025 - a compound annual growth rate (CAGR) of 9.5%. Factors such as…
Neuromodulation Market worth $10.4 billion by 2027
Neuromodulation Market is projected to grow from USD 6.0 billion in 2022 to USD 10.4 billion by 2027, at a CAGR of 11.8% from 2022 to 2027, according to a new report by MarketsandMarkets™. The market is driven by government support for research on neurological disorder along with increasing prevalence of neurological disorders. Emerging economies are expected to provide lucrative growth opportunities for the market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=921&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral
The internal neuromodulation…
Neuromodulation Market: Charting Future Frontiers for 2030
The Neuromodulation market was valued USD 6.5 Billion in 2023 and projected to reach USD 15.3 Billion by 2030, growing at a CAGR of 13.0% during the forecast period of 2024-2030.
The Neuromodulation Market report studies the competitive environment of the Neuromodulation Market based on company profiles and their efforts to increase product value and production. The Neuromodulation Market report discusses various factors driving or restraining the market, which will help…
Incontinence Neuromodulation Market - Reclaiming Independence, Redefining Well-b …
Newark, New Castle, USA: The "Incontinence Neuromodulation Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Incontinence Neuromodulation Market: https://www.growthplusreports.com/report/incontinence-neuromodulation-market/8696
This latest report researches the industry structure, sales, revenue,…
Neuromodulation Devices Market Insights, Forecast to 2030
The report extensively examines the global Neuromodulation Devices market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Neuromodulation Devices . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
Neuromodulation Market Outlook 2022-2028
Neurological issues are characterized as problems that influence the mind as well as the nerves tracked down all through the human body and the spinal rope. Intense spinal line injury, Alzheimer's sickness, amyotrophic horizontal sclerosis (ALS), ataxia, chime paralysis, mind cancers, cerebral aneurysm, epilepsy, and seizures are a portion of the normal neurological issues. The biochemical, underlying, or electrical irregularities in the mind, spinal line, or different nerves bring about…
